FEDIFAR: Andalusia limits access of Andalusian society to all medicinal products authorised by the Ministry.

-the patron saint of pharmaceutical distribution (FEDIFAR) considers that the Junta de Andalucía limited their citizens access to all medicinal products authorised by the Ministry of health, that the pharmacy can only dispense presentation wins the contest when the recipe is for active ingredient

– is put at risk the adequate supply of the market, to reduce the supply of important therapeutic groups to one or two manufacturers. Any impact on the production of these manufacturers would lead to lack of supply

-sector has undergone in the years 2010 and 2011, at the State level, of very harsh measures which have placed the companies on the verge of its feasibility. This is another measure that returns to attack the already ailing situation of enterprises. In addition, to break the rules of the game of the Spanish pharmaceutical model will cause economic damage added in businesses, beyond the desired savings

Andalusia, December of 2011- the Federation of pharmaceutical distribution (FEDIFAR) rejects the public contest of medicines contained in Decree-Lawadopted last Thursday by the Parliament of Andalusia with the votes of PSOE and IULV-CA, to select submissions provided in Andalusian pharmacies. Employers believed that the Andalusian Government limits and puts at risk the current access of the Andalusian citizenship to all medicinal products authorised by the Ministry of health, social services and equality.

The public tender will leave out of the market to all laboratories who did not win the contest. This could compromise the pharmaceutical provision they receive the Andalusians and it involves a change in the rules of the game, and you can therefore have effects on the balance of all operators in the sector: pharmacies, distribution and pharmaceutical industry.

how limited the access to medicines?

In the active ingredients affected by the measure, the Andalusians only eligible to the drug’s manufacturer to win the contest of supply and not to the whole of this active principle presentations authorised by the Ministry of health, Social Affairs and equality.

In addition, condition the provision of a population of 8.4 million to a single manufacturer (or two, as expected the Board) entails an enormous risk for the continuity of treatment, since that could give supply misconduct by any unforeseen and unpredictable imbalance in the production.

2010 And 2011 measures

Pharmaceutical distribution companies (and the sector of the medicinal product in general) already suffered a blow in their income statements, last year which has led to 1,190 million euros less than income. And this year, the Government has cut the pharmaceutical invoice with an unknown impact, but expected of EUR 2,400 million savings, amount that is subtracted from the income of the companies in the sector.

This adds to the constant cuts prices of recent years, inter alia, by the introduction of the system of reference prices. Not to mention, that the companies responsible to all corners of Spain carry all medications have seen how in less than ten years its margin (set by law) has declined 40%.

Commitment to the sustainability of public health

In recent years, Andalucia has taken steps to reduce the costs of pharmaceutical spending, mainly on the supply of medicinal products, i.e., cut of the income of operators in the sector. A sector that has shown its commitment to the sustainability of the Andalusian health service (SAS) and has collaborated in the implementation underway of the proposed measures.

On the other hand, operate eleven distribution companies of full range (associated with FEDIFAR), engine of wealth to the region in Andalusia. These firms have 30 stores distributed drugs throughout the community, employing skilled workers, invest in the latest technologies, in day to day help pharmacists with resolution of doubts of any kind and, above all, deal with each patient to find the necessary medication for his illness in your pharmacy. This is what is being at risk.

Without forgetting the fragmentation of the Spanish market which represent measures as approved by Andalucia. Many companies in the sector operating at the national level and need uniform rules of the game. So in the pharmaceutical distribution.

About us

The Federation of pharmaceutical distributors (FEDIFAR) is composed of 52 wide range distribution companies, with a combined market share above 97%.

High-end pharmaceutical distribution makes it possible that the entire Spanish population has equal access to medicines irrespective of the place where they reside. His activity means that all pharmacies of the territory receive equal all drugs marketed in Spain.

To achieve this, the distribution of wide range is based on the solidarity model of distribution: detract benefits of expensive products and high rotation to subsidize the service of cheap products and low rotation.